BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR)

BNP Paribas Financial Markets boosted its position in ProQR Therapeutics (NASDAQ:PRQR) by 14.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 58,801 shares of the biopharmaceutical company’s stock after acquiring an additional 7,300 shares during the period. BNP Paribas Financial Markets owned about 0.07% of ProQR Therapeutics worth $107,000 at the end of the most recent reporting period.

Separately, OneDigital Investment Advisors LLC boosted its holdings in shares of ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 15,550 shares during the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Price Performance

NASDAQ PRQR opened at $2.57 on Thursday. The business’s 50-day simple moving average is $3.45 and its 200-day simple moving average is $2.41. The firm has a market capitalization of $209.92 million, a P/E ratio of -8.03 and a beta of 0.24. ProQR Therapeutics has a 1-year low of $1.61 and a 1-year high of $4.62.

Analysts Set New Price Targets

Several research firms recently commented on PRQR. Raymond James upgraded ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. JMP Securities restated a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.60.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).